Business
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
– Cabozantinib reduced the risk of disease progression or death by 78%; hazard ratio = 0.22,
About this update from Exelixis, Inc.
[{"type":"text","content":"\n– Cabozantinib reduced the risk of disease progression or death by 78%; hazard ratio = 0.22, (p","length":168,"tagName":"div"}]